Litfulo▼ (ritlesitinib): Updated recommendations to minimize the risk of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality.
For the full text of the announcement click here.
Litfulo▼ (ritlesitinib): Updated recommendations to minimize the risk of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality.
For the full text of the announcement click here.


Data Protection Officer: dpo at eof dot gr